200-Page Report Tracks Unicycive's PDUFA-Bound Oxylanthanum Carbonate and Ardelyx's Tenapanor as a Market Built on Aging Binders Shifts Toward Novel Mechanisms

Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Hyperphosphatemia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

The "Hyperphosphatemia - Market Insights, Epidemiology and Market Forecast - 2036" report provides a comprehensive assessment of the hyperphosphatemia market across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. Covering historical and forecast data from 2022 to 2036, the report evaluates epidemiology, treatment practices, marketed and emerging therapies, competitive dynamics, market access, drug uptake, and commercial opportunities.

Hyperphosphatemia Market Overview

Hyperphosphatemia frequently remains asymptomatic or underdiagnosed during its early stages. Diagnosis primarily relies on serum phosphate measurement supported by assessments of calcium, magnesium, creatinine, blood urea nitrogen, vitamin D, and parathyroid hormone levels. Routine monitoring is particularly important for patients with advanced chronic kidney disease (CKD), end-stage renal disease (ESRD), and dialysis dependence.

Management focuses on reducing phosphate burden and limiting complications associated with CKD-mineral and bone disorder, secondary hyperparathyroidism, vascular calcification, and cardiovascular disease. Current strategies include dietary phosphate restriction, dialysis optimization, phosphate binders, intestinal phosphate absorption inhibitors, and management of associated metabolic abnormalities. Hemodialysis may be required in severe cases involving substantial renal impairment.

The hyperphosphatemia market is expected to expand steadily through 2036, supported by the increasing prevalence of CKD and ESRD, growth in dialysis populations, ageing demographics, and the rising incidence of diabetes and hypertension. Greater recognition of phosphate-related cardiovascular risk and increasing demand for therapies with improved tolerability and lower treatment burden are also contributing to market development.

Current Hyperphosphatemia Treatment Landscape

Phosphate binders remain central to hyperphosphatemia treatment. Marketed options include sevelamer carbonate (RENVELA/RENAGEL), lanthanum carbonate (FOSRENOL), ferric citrate (AURYXIA), sucroferric oxyhydroxide (VELPHORO), and calcium-based binders. Tenapanor (XPHOZAH), an intestinal phosphate absorption inhibitor, has introduced a differentiated mechanism for adults with CKD receiving dialysis.

Despite the availability of multiple therapies, sustained serum phosphate control remains difficult. Conventional phosphate binders may require a high number of tablets and can be associated with gastrointestinal adverse events, poor adherence, and long-term safety concerns. Calcium-based products may increase calcium exposure, while aluminum-based agents carry recognized safety limitations. These factors are accelerating interest in non-calcium binders, optimized formulations, and novel therapies targeting intestinal phosphate transport.

Calcium-based phosphate binders: Calcium acetate and calcium carbonate continue to be used, although concerns about calcium loading and vascular calcification may restrict long-term use.
Non-calcium phosphate binders: Sevelamer and lanthanum-based therapies reduce phosphate exposure without increasing calcium burden. Next-generation products are being developed to improve convenience and adherence.
Iron-based phosphate binders: Ferric citrate and sucroferric oxyhydroxide provide phosphate-lowering activity, with potential iron-related benefits for selected dialysis patients.
Phosphate absorption inhibitors: Tenapanor targets intestinal phosphate absorption through NHE3 inhibition and may be used as a differentiated option within the treatment algorithm.

Hyperphosphatemia Epidemiology

The epidemiological burden increases with CKD severity and is particularly significant among dialysis-dependent patients. In the United States, prevalent CKD cases during 2025 were highest among adults aged 65 years and older, followed by those aged 45-64 years. Historical estimates also indicate substantial growth in the treated ESRD population, with most affected patients receiving dialysis and the remainder living with functioning kidney transplants.

Published findings show that hyperphosphatemia is more common in advanced CKD than in early-stage disease. Among patients with ESRD, reported prevalence ranges from approximately 50% to 74%. Elevated serum phosphate levels are associated with vascular calcification, cardiovascular disease, hospitalization, and increased all-cause mortality, reinforcing the need for regular monitoring and durable treatment.

Approved and Emerging Hyperphosphatemia Therapies

Tenapanor (XPHOZAH), developed by Ardelyx, received US Food and Drug Administration approval in October 2023 for reducing serum phosphorus in adults with CKD on dialysis. Its clinical program included the Phase III PHREEDOM, BLOCK, and AMPLIFY studies, which demonstrated significant serum phosphorus reductions. The product provides an alternative to conventional phosphate-binding therapies and is expected to gain adoption as clinicians seek differentiated treatment options.

Sevelamer carbonate (RENVELA), marketed by Sanofi, remains an established non-calcium phosphate binder for patients with CKD on dialysis. Although it continues to hold an important position in treatment, branded sales face pressure from generic competition.

The hyperphosphatemia pipeline includes therapies intended to improve efficacy, reduce pill burden, and support long-term adherence. Taisho Pharmaceutical is evaluating TS-172 in a randomized, placebo-controlled Phase III study involving patients with hyperphosphatemia undergoing hemodialysis. Unicycive Therapeutics is advancing oxylanthanum carbonate, a product designed to require fewer and smaller tablets than many existing binders. Libang Pharmaceuticals has also completed enrollment in a global Phase III pivotal trial evaluating AP301.

Leading and emerging companies in the competitive landscape include Ardelyx, Sanofi, Taisho Pharmaceutical, Unicycive Therapeutics, Alebund Pharmaceuticals, and Libang Pharmaceuticals.

Key Hyperphosphatemia Market Drivers

Growth in CKD, ESRD, and dialysis-dependent patient populations worldwide.
Increasing awareness of the relationship between elevated phosphate levels, vascular calcification, cardiovascular morbidity, and mortality.
Greater clinical preference for non-calcium and iron-based phosphate binders.
Demand for lower pill burden, improved gastrointestinal tolerability, and better adherence.
Development of therapies targeting intestinal phosphate absorption and transport pathways.
Expanding healthcare expenditure and improvements in CKD monitoring and diagnosis.

Unmet Needs and Commercial Opportunities

Major unmet needs include delayed diagnosis, difficulty maintaining long-term phosphate control, poor adherence, gastrointestinal tolerability issues, dialysis dependence, and persistent cardiovascular and CKD-mineral and bone disorder risks despite treatment. The market continues to require convenient, well-tolerated therapies capable of delivering durable phosphate reduction across diverse patient groups.

Commercial uptake of emerging products will depend on comparative efficacy, safety, administration requirements, pill burden, reimbursement, and evidence of sustained benefit. Market access will also be shaped by pricing relative to clinical value, formulary positioning, dialysis reimbursement policies, and potential supplemental payment mechanisms for qualifying renal therapies.

Report Scope and Strategic Insights

The report applies epidemiology-based, bottom-up forecasting to assess the hyperphosphatemia treatment-addressable market, therapy-level revenue, patient uptake, peak market share, and regional growth potential through 2036. It includes detailed profiles of approved and pipeline therapies, clinical development analysis, competitive benchmarking, pricing trends, analogue assessment, market access considerations, and country-level treatment practices.

Primary research incorporates perspectives from more than 10 key opinion leaders and subject-matter experts, including clinicians and researchers affiliated with prominent academic and medical institutions. These insights support the assessment of prescribing behavior, therapy switching, treatment adherence, accessibility challenges, epidemiology, and the expected adoption of emerging hyperphosphatemia drugs.

The analysis also includes SWOT and conjoint assessments. Emerging therapies are evaluated according to efficacy, safety, tolerability, route and frequency of administration, expected market-entry timing, probability of success, and addressable patient population. This framework helps identify leading products, competitive threats, and high-value opportunities within the 7MM hyperphosphatemia market.

Reasons to Access the Report

Evaluate historical and forecast hyperphosphatemia market trends from 2022 to 2036.
Understand patient burden, diagnosis patterns, and epidemiological changes across the 7MM.
Assess approved therapies, late-stage pipeline candidates, and emerging mechanisms of action.
Compare drug uptake, peak patient share, pricing, reimbursement, and market-access potential.
Identify unmet needs and opportunities for differentiated product development and launch strategies.
Support portfolio planning, competitive intelligence, investment analysis, and evidence-based commercial decisions.

Overall, the hyperphosphatemia therapeutics market is shifting from traditional phosphate binder-based management toward lower-burden formulations and mechanism-based treatments. Continued growth in CKD and dialysis populations, combined with demand for improved phosphate control, is expected to create meaningful opportunities for established market participants and emerging companies through 2036.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Executive Summary of Hyperphosphatemia

4. Key Events of Hyperphosphatemia
4.1. Upcoming Key Catalysts
4.2. Key Conferences and Meetings
4.3. Key Transactions and Collaborations
4.4. News Flow

5. Epidemiology and Market Methodology of Hyperphosphatemia

6. Hyperphosphatemia Market Overview at a Glance
6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
6.2. Market Share of Hyperphosphatemia By Therapies (%) in the 7MM in 2025
6.3. Market Share of Hyperphosphatemia By Therapies (%) in the 7MM in 2036

7. Disease Background and Overview of Hyperphosphatemia
7.1. Introduction
7.2. Causes
7.3. Signs and Symptoms
7.4. Developmental and Clinical Aspects
7.5. Pathophysiology
7.6. Clinical manifestations
7.7. Diagnosis

8. Treatment and Guidelines of Hyperphosphatemia
8.1. Treatment Algorithm

9. Epidemiology and Patient Population of Hyperphosphatemia
9.1. Key Findings
9.2. Assumptions and Rationale: The 7MM
9.2.1. Total Incident cases of Hyperphosphatemia in the 7MM
9.3. The US
9.3.1. Total Prevalent Cases of Hyperphosphatemia in the United States
9.3.2. Total Diagnosed Prevalent Cases of Chronic Kidney Disease in the United States
9.3.3. Stage-specific Distribution of Chronic Kidney Disease in the United States
9.3.4. Total Prevalent Cases of End-Stage Renal Disease in the United States
9.3.5. Number of ESRD Patients Undergoing Dialysis in the United States
9.3.6. Total Prevalent Cases of Hyperphosphatemia in the United States
9.4. EU4 and the UK
9.4.1. Total Prevalent Cases of Hyperphosphatemia in EU4 and the UK
9.4.2. Total Diagnosed Prevalent Cases of Chronic Kidney Disease in EU4 and the UK
9.4.3. Stage-specific Distribution of Chronic Kidney Disease in EU4 and the UK
9.4.4. Total Prevalent Cases of End-Stage Renal Disease in EU4 and the UK
9.4.5. Number of ESRD Patients Undergoing Dialysis in EU4 and the UK
9.4.6. Total Prevalent Cases of Hyperphosphatemia in EU4 and the UK
9.5. Japan
9.5.1. Total Prevalent Cases of Hyperphosphatemia in Japan
9.5.2. Total Diagnosed Prevalent Cases of Chronic Kidney Disease in Japan
9.5.3. Stage-specific Distribution of Chronic Kidney Disease in Japan
9.5.4. Total Prevalent Cases of End-Stage Renal Disease in Japan
9.4.5. Number of ESRD Patients Undergoing Dialysis in Japan
9.4.6. Total Prevalent Cases of Hyperphosphatemia in Japan

10. Patient Journey of Hyperphosphatemia

11. Marketed Drugs
11.1. Competitive Landscape: Marketed Therapies
11.2. Tenapanor (XPHOZAH): Ardelyx
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Summary of Pivotal Trials
11.2.5. Analyst Views
11.3. Lanthanum Carbonate (FOSRENOL): Takeda Pharmaceutical
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Other Developmental Activities
11.3.4. Summary of Pivotal Trials
11.3.5. Analyst Views
List to be continued in the report..

12. Emerging Drugs
12.1. Competitive Landscape of Emerging Therapies
12.2. Oxylanthanum Carbonate: Unicycive Therapeutics
12.2.1. Product Description
12.2.2. Other Development Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Analyst Views
12.3. AP-301: Alebund Pharmaceuticals
12.3.1. Product Description
12.3.2. Other Development Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Analyst Views
List to be continued in the report..

13. Hyperphosphatemia: Seven Major Market Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Conjoint Analysis
13.4. Key Market Forecast Assumptions
13.4.1. Cost Assumptions and Rebates
13.4.2. Pricing Trends
13.4.3. Analogue Assessment
13.4.4. Launch Year and Therapy Uptakes
13.5. Total Market Size of Hyperphosphatemia in the 7MM
13.6. The United States Market Size
13.6.1. Total Market Size of Hyperphosphatemia in the United States
13.6.2. Market Size of Hyperphosphatemia by Therapies in the United States
13.7. EU4 and the UK Market Size
13.7.1. Total Market Size of Hyperphosphatemia in EU4 and the UK
13.7.2. Market Size of Hyperphosphatemia by Therapies in EU4 and the UK
13.8. Japan Market Size
13.8.1. Total Market Size of Hyperphosphatemia in Japan
13.8.2. Market Size of Hyperphosphatemia by Therapies in Japan

14. Unmet Needs of Hyperphosphatemia

15. SWOT Analysis of Hyperphosphatemia

16. KOL Views of Hyperphosphatemia
16.1. Expert/KOL Interview Highlights

17. Market Access and Reimbursement of Hyperphosphatemia
17.1. United States
17.1.1. Centre for Medicare and Medicaid Services (CMS)
17.2. EU4 and the UK
17.2.1. Germany
17.2.2. France
17.2.3. Italy
17.2.4. Spain
17.2.5. United Kingdom
17.3. Japan
17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
17.5. Market Access and Reimbursement of Hyperphosphatemia Therapies

18. Appendix
18.1. Bibliography
18.2. Report Methodology

19. Analyst's Capabilities

20. Disclaimer

21. About the Publisher

List of Tables
Table 1: Summary of hyperphosphatemia, Market, Epidemiology, and Key Events (2021-2034)
Table 2: Total Prevalent Cases of Hyperphosphatemia in 7MM, (2022-2036)
Table 3: Total Prevalent Cases of CKD in the United States (2022-2036)
Table 4: Total Diagnosed Prevalent Cases of CKD in the United States (2022-2036)
Table 5: Stage-specific Distribution of CKD in the United States (2022-2036)
Table 6: Total Prevalent Cases of ESRD in the United States (2022-2036)
Table 7: Number of ESRD Patients Undergoing Dialysis in the United States (2022-2036)
Table 8: Total Prevalent Cases of Hyperphosphatemia in the United States (2022-2036)
Table 9: Total Prevalent Cases of CKD in EU4 and the UK (2022-2036)
Table 10: Total Diagnosed Prevalent Cases of CKD in EU4 and the UK (2022-2036)
Table 11: Stage-specific Distribution of CKD in EU4 and the UK (2022-2036)
Table 12: Total Prevalent Cases of ESRD in EU4 and the UK (2022-2036)
Table 13: Number of ESRD Patients Undergoing Dialysis in EU4 and the UK (2022-2036)
Table 14: Total Prevalent Cases of Hyperphosphatemia in EU4 and the UK (2022-2036)
Table 15: Total Prevalent Cases of CKD in Japan (2022-2036)
Table 16: Total Diagnosed Prevalent Cases of CKD in Japan (2022-2036)
Table 17: Stage-specific Distribution of CKD in Japan (2022-2036)
Table 18: Total Prevalent Cases of ESRD in Japan (2022-2036)
Table 19: Number of ESRD Patients Undergoing Dialysis in Japan (2022-2036)
Table 20: Total Prevalent Cases of Hyperphosphatemia in Japan (2022-2036)
Table 21: Organizations contributing toward the fight against Hyperphosphatemia
Table 22: Comparison of marketed drugs
Table 23: Auryxia, Clinical Trial Description 2024
Table 24: Velphoro, Clinical Trial Description 2024
Table 25: Comparison of emerging drugs under development
Table 26: Total Hyperphosphatemia Market Size in the 7MM, in USD Million (2022-2036)
Table 27: Hyperphosphatemia Market Size by Therapies in the 7MM, in USD Million (2022-2036)
Table 28: Total Hyperphosphatemia Market Size in the US, in USD Million (2022-2036)
Table 29: Hyperphosphatemia Market Size by Therapies in the US, in USD Million (2022-2036)
Table 30: Total Hyperphosphatemia Market Size in EU4 and the UK, in USD Million (2022-2036)
Table 31: Hyperphosphatemia Market Size by Therapies in EU4 and the UK, in USD Million (2022-2036)
Table 32: Total Hyperphosphatemia Market Size in Japan, in USD Million (2022-2036)
Table 33: Hyperphosphatemia Market Size by Therapies in Japan, in USD Million (2022-2036)

List of Figures
Figure 1: Total Prevalent Cases of Hyperphosphatemia in 7MM, (2022-2036)
Figure 2: Total Prevalent Cases of CKD in the United States (2022-2036)
Figure 3: Total Diagnosed Prevalent Cases of CKD in the United States (2022-2036)
Figure 4: Stage-specific Distribution of CKD in the United States (2022-2036)
Figure 5: Total Prevalent Cases of ESRD in the United States (2022-2036)
Figure 6: Number of ESRD Patients Undergoing Dialysis in the United States (2022-2036)
Figure 7: Total Prevalent Cases of Hyperphosphatemia in the United States (2022-2036)
Figure 8: Total Prevalent Cases of CKD in EU4 and the UK (2022-2036)
Figure 9: Total Diagnosed Prevalent Cases of CKD in EU4 and the UK (2022-2036)
Figure 10: Stage-specific Distribution of CKD in EU4 and the UK (2022-2036)
Figure 11: Total Prevalent Cases of ESRD in EU4 and the UK (2022-2036)
Figure 12: Number of ESRD Patients Undergoing Dialysis in EU4 and the UK (2022-2036)
Figure 13: Total Prevalent Cases of Hyperphosphatemia in EU4 and the UK (2022-2036)
Figure 14: Total Prevalent Cases of CKD in Japan (2022-2036)
Figure 15: Total Diagnosed Prevalent Cases of CKD in Japan (2022-2036)
Figure 16: Stage-specific Distribution of CKD in Japan (2022-2036)
Figure 17: Total Prevalent Cases of ESRD in Japan (2022-2036)
Figure 18: Number of ESRD Patients Undergoing Dialysis in Japan (2022-2036)
Figure 19: Total Prevalent Cases of Hyperphosphatemia in Japan (2022-2036)
Figure 20: Total Hyperphosphatemia Market Size in the 7MM
Figure 21: Total Hyperphosphatemia Market Size in the United States
Figure 22: Hyperphosphatemia Market Size by Therapies in the US
Figure 23: Total Hyperphosphatemia Market Size in EU4 and the UK
Figure 24: Hyperphosphatemia Market Size by Therapies in EU4 and the UK
Figure 25: Total Hyperphosphatemia Market Size in Japan
Figure 26: Hyperphosphatemia Market Size by Therapies in Japan

A selection of companies mentioned in this report includes, but is not limited to:

Ardelyx
Sanofi
Takeda Pharmaceutical
Unicycive Therapeutics
Alebund Pharmaceuticals
Taisho Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/r/wa27e6

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900

Hyperphosphatemia Market Insight, Epidemiology, and Market Forecast to 2036 Now Available — See Which Novel Mechanism Could Unseat Sevelamer as Phosphate Binders Face a Pill-Burden Reckoning